NOTCH1 and acute lymphoblastic leukemia: For example, our data support current clinical trials and ongoing studies to treat NOTCH1-dependant T-ALL by repurposing FDA-approved HDAC inhibitor drugs, including Vorinostat, Romidepsin, Belinostat, and Panobinostat, which specifically target HDAC1 together with one or more other HDACs (57, 58).